Skip to main content
Premium Trial:

Request an Annual Quote

Warnex Sells Pathogen Dx Business to AES Labs for $859K

NEW YORK (GenomeWeb News) — Warnex has sold its pathogen-detection business to AES Laboratoire, a French lab-equipment supplier, for CAN$900,000 ($859,000) in cash.
 
Warnex CEO Mark Busgang said yesterday it transferred the assets last week, and said that the deal is part of his company’s strategy to focus on laboratory services.
 
Quebec-based Warnex said around CAN$300,000 is to be paid at closing, and the other two thirds of the price would be paid in two installments on the first and second anniversaries of the closing.
 
Terms of the agreement also call for AES to rent 4,300 square feet of Warnex’ manufacturing and lab facilities for as long as two years.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.